These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
636 related articles for article (PubMed ID: 33735711)
1. Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. Wassel MMS; Ammar YA; Elhag Ali GAM; Belal A; Mehany ABM; Ragab A Bioorg Chem; 2021 May; 110():104794. PubMed ID: 33735711 [TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M). Shaheen MA; El-Emam AA; El-Gohary NS Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080 [TBL] [Abstract][Full Text] [Related]
4. Design, microwave assisted synthesis, and molecular modeling study of some new 1,3,4-thiadiazole derivatives as potent anticancer agents and potential VEGFR-2 inhibitors. Atta-Allah SR; AboulMagd AM; Farag PS Bioorg Chem; 2021 Jul; 112():104923. PubMed ID: 33932767 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Elmetwally SA; Saied KF; Eissa IH; Elkaeed EB Bioorg Chem; 2019 Jul; 88():102944. PubMed ID: 31051400 [TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers. Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel N-(3-amino-4-methoxyphenyl)acrylamide derivatives as selective EGFR Ding S; Dong X; Gao Z; Zheng X; Ji J; Zhang M; Liu F; Wu S; Li M; Song W; Shen J; Duan W; Liu J; Chen Y Bioorg Chem; 2022 Jan; 118():105471. PubMed ID: 34798457 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers. Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140 [TBL] [Abstract][Full Text] [Related]
10. Discovery of new quinolines as potent colchicine binding site inhibitors: design, synthesis, docking studies, and anti-proliferative evaluation. Hagras M; El Deeb MA; Elzahabi HSA; Elkaeed EB; Mehany ABM; Eissa IH J Enzyme Inhib Med Chem; 2021 Dec; 36(1):640-658. PubMed ID: 33588683 [TBL] [Abstract][Full Text] [Related]
11. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies. Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724 [TBL] [Abstract][Full Text] [Related]
12. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937 [TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of novel Thiazolo[5,4-b]pyridine derivatives as potent and selective EGFR-TK inhibitors targeting resistance Mutations in non-small cell lung cancer. Borude AS; Deshmukh SR; Tiwari SV; Kumar SH; Thopate SR Eur J Med Chem; 2024 Oct; 276():116727. PubMed ID: 39094428 [TBL] [Abstract][Full Text] [Related]
14. Synthesis, biological evaluation, and molecular docking studies of cinnamic acyl 1,3,4-thiadiazole amide derivatives as novel antitubulin agents. Yang XH; Wen Q; Zhao TT; Sun J; Li X; Xing M; Lu X; Zhu HL Bioorg Med Chem; 2012 Feb; 20(3):1181-7. PubMed ID: 22261027 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors. Zhou Z; He J; Yang F; Pan Q; Yang Z; Zheng P; Xu S; Zhu W Bioorg Chem; 2021 Jul; 112():104848. PubMed ID: 33819737 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation. Su Z; Yang T; Wang J; Lai M; Tong L; Wumaier G; Chen Z; Li S; Li H; Xie H; Zhao Z Bioorg Med Chem Lett; 2020 Aug; 30(16):127327. PubMed ID: 32631532 [TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis and Cytotoxic Evaluation of Novel Chalcone Derivatives Bearing Triazolo[4,3-a]-quinoxaline Moieties as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects. Alswah M; Bayoumi AH; Elgamal K; Elmorsy A; Ihmaid S; Ahmed HEA Molecules; 2017 Dec; 23(1):. PubMed ID: 29280968 [TBL] [Abstract][Full Text] [Related]